AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to ...

AstraZeneca’s lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel ...

A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.

Photo: Graeme Sloan/Bloomberg News AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients.

(Sharecast News) - AstraZeneca updated the market on two ongoing drug trials on Monday, with a key trial in breast cancer failing to improve survival. The FTSE 100 pharmaceutical giant said the ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast cancer compared to chemotherapy.

AstraZeneca's breast cancer drug combination fails in late-stage trial Triple-negative breast cancer remains one of the most challenging forms of disease to treat due to the lack of known ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast cancer compared to chemotherapy.